Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities of daily living.Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AChR antibody-positive gMG in the EU. The Committee for

Ultomiris recommended for EU approval for gMG

25 July 07:05 BST Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities of daily living Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris would be the first

Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu is the first HER2-directed therapy to demonstrate a survival benefit in this population. Application being evaluated under FDA Real-Time Oncology Review and Project Orbis.AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-negative) breast

High-Performance High-Value Forte™ Sim Racing Pedal Set from Asetek SimSports™ Now Shipping

Advanced Load-Cell Brake Pedals from Asetek for Immersive Sim RacingAalborg, Denmark – July 25, 2022 –– Asetek, sim racing gear innovator, the creator of the all-in-one liquid cooler, and the global leader in liquid cooling solutions for gaming PCs and DIY enthusiasts, today announced it has started shipping its high-performance Forte™ Throttle and Brake Pedal Set for immersive sim racing. Forte means “strong” and with the Forte™ Pedal Set from Asetek SimSports™ aspiring sim racers can experience high-end pedals for immersive racing at a very competitive price point, while still providing a

First day of trading in Collector Bank is expected to be on 15 August 2022 – Collector AB applies for delisting

After the approval from the Swedish Financial Supervisory Authority on 21 July 2022 that the intra-group merger between Collector AB (publ) (”Collector AB”) and Collector Bank AB (”Collector Bank”) may be executed, the Board of Collector AB has resolved to apply for delisting of the shares in Collector AB from Nasdaq Stockholm. Nasdaq Stockholm has previously approved the listing of the shares in Collector Bank subject to customary conditions. Collector AB hereby informs of a preliminary timetable. The merger is expected to be completed on 15 August 2022.The Swedish Financial Supervisory

Interim Report 1 January - 30 June 2022

Strong quarter despite increased uncertaintySECOND QUARTER The second quarter of the year was strong in terms of profitability and EBITDA amounted to SEK 173 million compared with SEK 146 million the previous year. Net sales during the quarter amounted to SEK 1,009 million, compared with SEK 826 million last year, an increase of 22%. The higher net sales are explained by higher sales prices for all products and increased sales volumes in the Joinery product area.   The improved result compared to the previous year is explained by higher sales prices for Sawn Wood, increased sales

Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

25 July 2022 07:00 BST Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to demonstrate a survival benefit in this population Application being evaluated under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the

GomSpace (provider of nanosatellites) announces its quarterly results for the second quarter 2022

Stockholm, July 25, 2022. GomSpace Group AB (the “Company”) announces its interim report for the second quarter of 2022. The report is available on the Company’s homepage (www.gomspace.com). The following is taken from the quarterly report: Second quarter summary 1 April – 30 June 2022 (2021) · Order intake decreased by 78% to T.SEK 43,931 (199,459) The decrease is due to GomSpace in 2021 signed a large contract with Indra of EUR 14,5 million (147 million SEK) · Net revenues increased by 8% to T.SEK 51,253 (47,535) · Gross margin decreased to 6% (14%) · Operating profit (

Vinted UAB announces a recommended public offer of SEK 14.10 in cash per share to the shareholders of Rebelle AB (publ)

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important

Adolescent arterial stiffness – a novel risk factor for hypertension and insulin resistance in young adulthood and for type 2 diabetes mellitus in mid-adulthood

Emerging evidence suggests that arterial stiffness may be a novel risk factor to be targeted in the prevention and treatment of vascular and metabolic diseases from a young age, a review of studies published in the Journal of Hypertension concludes.The prevalence of hypertension and obesity has been on the increase globally, despite the targeted effort at promoting weight loss, increasing physical activity, and decreasing sedentary time in the general population. This global challenge informed a recent scientific statement from the American Heart Association on further research into obesity

Top 7 Online Casino Sites With UPI In India For 2022

Online casinos have become popularised over the last few years. Today, online casinos offer a diverse selection of games and deposit and withdrawal methods. Most recently, countries like India have adopted a range of casino payment methods, including the Unified Payments Interface (UPI). This real-time payment system has around 150 million monthly active users in India, and there are more than 300 banks available on UPI. Due to UPI’s rising popularity, there are several online casinos with UPI payment in India, and in this article, we will look at these platforms in detail.The Best UPI

Nordea Bank Abp: Repurchase of own shares on 22.07.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares22.07.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 22.07.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XHEL 400,000 9.31 3,725,160.00CEUX 274,555 9.31 2,557,290.87TQEX 31,126 9.31 289,896.19XSTO 400,000 9.31 3,

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 22.07.2022

United Bankers Plc NOTIFICATION   22.07.2022 at 18:30   UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 22.07.2022   Date 22.07.2022  Exchange transaction Buy  Share class UNITED  Amount 250  Average price/share 13.5000 EURHighest price/share 13.5000 EURLowest price/share 13.5000 EURTotal price 3,375.00 EUR        The shares held by United Bankers Plc on 22.07.2022:   UNITED 59,204         On behalf of United

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 22.07.2022

Fiskars Corporation   Stock Exchange Release 22.07.2022 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 22.07.2022   Date 22.07.2022  Exchange transaction Buy  Share class FSKRS  Amount  3,470  Average price/share 19.0080 EURHighest price/share 19.0800 EURLowest price/share 18.8200 EURTotal price 65,957.76 EUR        The shares held by Fiskars Corporation on 22.07.2022:   FSKRS 882,731       On

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 22.07.2022

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION    22.07.2022 at 18:30 EET   ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 22.07.2022   Date 22.07.2022  Exchange transaction Buy  Share class ALEX  Amount 35  Average price/share 7.7600   EURHighest price/share 7.7600 EURLowest price/share 7.7600 EURTotal price 271.60 EUR        The shares held by Alexandria Pankkiiriliike Oyj on 22.07.

Just announced: IFPA Forum - Asia will be held in Singapore July 2023

The second IFPA Forum will be held in July 2023 in Singapore, on the margins of the World Congress of Dermatology. This IFPA Forum will focus on the unmet needs of people living with psoriatic disease in Asia and their solutions.The IFPA Forum brings together people living with psoriatic disease, advocacy associations, and thought leaders from across the psoriatic disease community. It will spearhead a roadmap to implement the recommendations from the 2016 Global Report on Psoriasis.   “The focus of the IFPA Forum is to build consensus and find solutions to the unmet needs of all people

#22-253 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Xisi Guo leaves Optomed’s Board of Directors

Optomed Plc Stock Exchange Release 22 July 2022 at 17:00, Helsinki Xisi Guo leaves Optomed’s Board of Directors Xisi Guo has decided to leave the Board of Directors of Optomed 19 August 2022 as he decided to leave his position at Cenova Capital, Optomed’s largest shareholder. After the change, Optomed’s Board of Directors will consist of four members: Petri Salonen (chair), Seppo Mäkinen, Reijo Tauriainen and Anna Tenstam.   According to Optomed’s articles of association, Optomed’s Board shall consist of at least five members. Consequently, Optomed’s Board will convene an

Trelleborg acquires manufacturer of aerospace components

Trelleborg Group has, through its business area Trelleborg Sealing Solutions, signed an agreement to acquire the German-based company MG Silikon GmbH, an entity within Saint-Gobain Group. The company specializes in sealing solutions for aerospace and industrial applications. Closing of the transaction is subject to approvals from relevant authorities.   The company has its head office and manufacturing in Lindau, Germany, and has annual sales of approximately SEK 120 M.   “The aerospace industry is recovering strongly after the pandemic, and is expected to show healthy growth

Wärtsilä Corporation - Manager's transaction: Tuomela, Tiina

Wärtsilä Corporation, Managers' transactions, 22.7.2022 at 16:35 EESTWärtsilä Corporation - Manager's transaction: Tuomela, TiinaWärtsilä's Annual General Meeting held on 3 March 2022 decided that approximately 40% of the annual fee to the members of the Board of Directors be paid in Wärtsilä shares. Pursuant to this decision, shares have been acquired as follows to member of the Board Tiina Tuomela: Wärtsilä Corporation - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tiina Tuomela Position: Member

Wärtsilä Corporation - Manager's transaction: Rahmström, Mats

Wärtsilä Corporation, Managers' transactions, 22.7.2022 at 16:30 EESTWärtsilä Corporation - Manager's transaction: Rahmström, MatsWärtsilä's Annual General Meeting held on 3 March 2022 decided that approximately 40% of the annual fee to the members of the Board of Directors be paid in Wärtsilä shares. Pursuant to this decision, shares have been acquired as follows to member of the Board Mats Rahmström: Wärtsilä Corporation - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mats Rahmström Position:

Wärtsilä Corporation - Manager's transaction: Forssell, Johan

Wärtsilä Corporation, Managers' transactions, 22.7.2022 at 16:25 EESTWärtsilä Corporation - Manager's transaction: Forssell, JohanWärtsilä's Annual General Meeting held on 3 March 2022 decided that approximately 40% of the annual fee to the members of the Board of Directors be paid in Wärtsilä shares. Pursuant to this decision, shares have been acquired as follows to member of the Board Johan Forssell: Wärtsilä Corporation - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Johan Forssell Position:

There are no items matching the current filter
There are no more items matching the current filter
Back to top